TP53 disruption is considered to be the most important prognostic factor in chronic lymphocytic leukemia (CLL), but not all patients with TP53 disruption have similar dismal outcomes. We evaluated the prognostic value of TP53 disruption in CLL patients without treatment indications.
In addition, the prevalence of CLL may increase because of the trend of aging population. Moreover, the proportion of newly diagnosed and asymptomatic CLL patients seems to increase due to the popularization of health examination. CLL patients have heterogeneous clinical course. The prognostic assessment of CLL patients mainly relies on biological and clinical parameters. TP53 maps to 17p13.1 and is considered to be the most important prognostic factor in CLL. TP53 disruption, resulting from either a 17p deletion (del(17p)) or TP53 mutations, is almost always associated with advanced stage of disease, short time to first treatment (TTFT) and dismal survival. TP53 is an extremely important regulator of the DNA damage pathway; hence, patients carrying TP53 disruption respond poorly to genotoxic chemotherapies. 3 Thus, these patients abandon the standard chemoimmunotherapy and are recommended novel agents or to be treated in clinical trials. 4 In newly diagnosed CLL patients, TP53 disruption is relatively infrequent (5%-10%), while the frequency increases during the progression of disease, and may reach up to 50% at refractoriness. 2, 5, 6 Previous studies have found that the majority (70%) of patients
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carrying del(17p) also harbored TP53 mutations in the remaining allele 7 and 40% of patients carried isolated TP53 mutations. 8 Those studies have established the fact that del(17p) and TP53 mutations conveys a poor outcome.
2,9-11
We observed that not all CLL patients with TP53 disruption have similarly dismal outcomes in our study. A proportion of patients with TP53 disruption showed a relatively prolonged period of TTFT and OS. These patients need regular follow-up. To date, few studies have investigated the reasons for these heterogeneous clinical courses and outcomes in newly diagnosed CLL patients with TP53 disruption. The aim of our article was to identify the correlation between TTFT and TP53 disruption and guide patients to follow up more effectively.
| MATERIALS AND METHODS

| Patients
Three hundred and five newly diagnosed Chinese CLL patients between July 2005 and June 2017, who were asymptomatic and adopted a watch-and-wait approach until treatment indications, were enrolled in this study. Patients with evidence of treatment indications at the time of initial CLL diagnosis were excluded from the study. The diagnosis of each patient was based on the International Workshop on CLL-National Cancer Institution (iwCLL) criteria. 12 The clonality of each patient's circulating B lymphocytes was confirmed by flow cytometry. Cytogenetic examinations and other clinical assessments were performed at diagnosis. When patients developed progressive or symptomatic disease state, the therapeutic schedule was proposed by hematologists according to the updated iwCLL criteria. Initial therapies and long-term outcomes of the subjects were confirmed by follow-up telephone call.
This study was approved by the First Affiliated Hospital of Nanjing Medical University.
| Analyses of cytogenetics
Fluorescence in situ hybridization (FISH) analysis was performed in most cases, including del(17p) (n = 305), 11q deletion (del(11q)) (n = 253), trisomy 12 (+12) (n = 237), and 13q deletion (del(13q)) (n = 194), using the following fluorescent-labeled probes: LSI p53 (17p13), LSI ATM (11q22), CEP12 (centromere 12), and LSI D13S319 (13q14). All the probes were purchased from Vysis (Abbott Park, IL).
The signal screening was performed on more than 300 cells with well depicted signals. As published before, the cutoff levels were 5.2%, 7.7%, 3.0%, and 10.3% for del(17p), del(11q), +12, and del(13q), respectively. Analyses of metaphase cytogenetics were carried out on peripheral blood samples (n = 254) by the approach described previously. 10 More than 20 metaphases were analyzed. Complex karyotype (CK) was defined as ≥3 chromosome aberrations detected in at least two metaphases. 13 
| Analyses of TP53 and IGHV mutations
The QIAamp DNA Blood Kits (QIAGEN, Düsseldorf, Germany) were used to separate genomic DNA from peripheral blood mononuclear cells according to the manufacturer's recommendations. Direct Sanger sequencing was used for detecting the mutation status of IGHV and exons 4-9 of TP53. 10 The mutated IGHV (M-IGHV) was defined as less than 98% germline homology.
| Detection of CD38 and ZAP-70
CD38 and ZAP-70 expressions were detected by flow cytometry as previously described. 14 The positive cutoff value of CD38 and ZAP-70 in CLL cells were 30% and 20%, respectively.
| Statistical analyses
Overall survival (OS) was defined as the time from the date of diagno- 
| Clinical and molecular characteristics of the CLL patients with TP53 disruption
Data on del(17p) and TP53 mutations were available for all the cases.
TP53 disruption was detected in 41 (13.6%) patients with 30 (9.8%) del(17p) and 26 (8.5%) TP53 mutations. The clinical and molecular characteristics of the patients with TP53 disruption are shown in Abbreviations: +, censored data; -, not applicable; F, female; M, male; OS, overall survival; TTFT, time to first treatment. ranged from 5.3% to 93%. TP53 mutations were detected at exon 4 in 3 cases (11.5%), exon 5 in 2 cases (7.7%), exon 6 in 1 case (3.8%), exon 7 in 9 cases (34.6%), and exon 8 in 11 cases (42.4%).
| Clinical characterizations stratified by del(17p) or TP53 mutations
The clinical characteristics stratified by del(17p) or TP53 mutations are shown in Table 3 . TP53 mutations were significantly associated with del(17p) (P < 0.001), Binet stage C (P = 0.03), IGHV unmutation (U-IGHV) (P < 0.001), and CK (P < 0.001). Del(17p) was detected more commonly in patients with CK (P < 0.001), Binet stage C (P < 0.001), β2-MG (P = 0.01), and del(11q) (P = 0.03). The most frequently used IGHV gene family was IGHV4 (54.1%), followed by IGHV3 (33.4%), IGHV1 (8.2%), IGHV5 (1.6%), and IGHV7 (1%). Del(17p) and TP53 mutations were more common in patients using IGHV1-69 (4 of 30 vs 5 of 232, P = 0.01; 4 of 21 vs 5 of 241, P = 0.001, respectively).
| The impact of TP53 disruption on prognosis
In the 305 CLL cases, the median TTFT was 82 months and median OS was not reached (NR) until the last follow-up time. In order to study the prognostic value of TP53 disruption, we divided the subjects into three groups: (1) patients without TP53 disruption (n = 264);
(2) patients with del(17p) (n = 30); and (3) patients with sole TP53 mutations (n = 11). The survival curves of these groups are shown in Table S1 . TTFT was significantly shorter in subjects with del(17p) than in those with sole TP53 mutation (median, 21 months vs NR, P = 0.03) and in patients without TP53 disruption (median 21 months vs 89 months, P < 0.001). The median OS of all the groups was NR and patients with del(17p) had shorter OS (P = 0.002). Nevertheless, sole TP53 mutations failed to show significant impact on TTFT or OS.
| Correlations between prognosis and the percentage of cells with del(17p)
To 
| Risk factors associated with survival in del(17p) group
In total, 30 patients harbored a del(17p). During the follow-up, 20 patients eventually developed progressive or symptomatic disease and received treatment while 9 patients had died (CLL-related death).
Univariate analyses were performed to assess the relations between potentially prognostic indicators and TTFT as well as OS. The results are shown in Table 5 . Considering patients who harbored del(17p), the median TTFT was 21 months after diagnosis (range 2-95 months).
The cumulative incidence of treatment at 12 and 36 months were 26.7% and 53.3%, respectively. Hazard analyses were performed to identify the risk factors associated with shorter TTFT (Figure 3 ). In the del(17p) group, TP53 mutation (P = 0.001), U-IGHV (P = 0.001), CK 
| Survival analysis based on cytogenetic clones
Among the 30 patients with del(17p), 28 harbored other cytogenetic aberrations. There was a great discrepancy in the percentage of cells involved in each aberration. Moreover, we studied whether TP53 subclones provided additional prognostic significance in CLL.
We considered there to be different clones if the difference in positive rates between two probes was more than 30%. Del(17p) was mutations, is considered to be the most important prognostic indicator. 5 Patients with TP53 disruption rarely achieve a complete remission by chemoimmunotherapy, resulting in overall poor outcomes. In this study, we included a cohort of 305 subjects to explore the prognostic value of TP53 disruption in newly diagnosed CLL patients without treatment indications. Previous researches showed that TP53 disruption could be detected in 5%-10% CLL patients at the time of initial diagnosis. 4 In our cohort, we identified that 13.4% patients harbored TP53 disruption, including 9.8% with del(17p) and 8.5% with TP53 mutations, which is similar to previous studies. 4 Previous studies have demonstrated that del(17p) and TP53 mutations convey a poor outcome. 10, [15] [16] [17] [18] In our investigation, del (17p) had a significant negative impact on TTFT and OS, while TP53 mutations without del(17p) failed to show significant clinical implications. This result may be explained by the fact that we excluded patients with evidence of treatment indications at the time of initial diagnosis, and TP53 mutations were reported to be early events in CLL disease progression and predicted rapid disease progression. In addition, patients with TP53 mutations and del(17p) had a worse outcome than those with del(17p) alone. In our study, patients with both Patients who presented with ≥50% del(17p) often had TP53 mutations (80%) and had the poorest prognosis. Patients with del(17p) had a heterogeneous outcome. We found that patients with high percentage (>25%) of del(17p) presented shorter TTFT and OS. Patients with low percentage (≤25%) of del(17p) presented shorter TTFT than patients without del(17p), this has not been seen in previous studies.
We evaluated the prognostic value of some other clinical indicators in patients with del(17p) and identified that IGHV status, β2-MG, age, TP53 mutation, and CK still provided additional prognostic significance. IGHV status, age, β2-MG, and TP53 mutation were the prognostic factors included in CLL-IPI, so our results support the conclusion that CLL-IPI can distinguish patients with high risk from low risk in del(17p) group. 21 Recently, CK was considered as one of the most important prognostic indicators associated with poor outcome, independently of CLL-IPI. 22 In the presence of del(17p), patients without CK had a significantly longer TTFT than those with CK. However, we observed no significant difference in OS between the two groups. This might be due to the short median follow-up time in our study. In multivariate analyses, β2-MG >3.5 mg/L was independently correlated with TTFT and OS in the del(17p) group. These results suggest that a subset of patients with del(17p) had a stable disease.
The majority of patients (93%) with del(17p) harbored other cytogenetic abnormalities. Recently, Yi et al 23 reported that the sizes of intratumoral genetic subclones have significant impact on the prognosis of CLL. In accordance with that report, we defined 30% as a cutoff value to identify different cytogenetic clones and investigated whether intratumoral genetic subclones might partially contribute to the prognostic heterogeneity of patients with del(17p). Our results indicated that patients with a del(17p) as a minor clone had a survival advantage compared with patients with a del(17p) as a major clone, in agreement with prior studies. 23, 24 Therefore, integrating analyses of the size of intratumoral genetic subclones identified by FISH provides more precise prognostic stratification of CLL patients with del(17p).
Regarding the retrospective nature, the limited number of CLL patients with TP53 disruption was another limitation in our study. So, large-scale multicenter prospective studies are needed to confirm our findings above.
In conclusion, we observed that CLL patients with TP53 disrup- 
